AbstractPulmonary dysfunction is a significant complication following allogeneic hematopoietic stem cell transplantation (HSCT), and is associated with significant morbidity and mortality. Effective antimicrobial prophylaxis and treatment strategies have increased the incidence of noninfectious lung injury, which can occur in the early posttransplant period or in the months and years that follow. Late-onset noninfectious pulmonary complications are frequently encountered, but diagnostic criteria and terminology for these disorders can be confusing and therapeutic approaches are suboptimal. As a consequence, inaccurate diagnosis of these conditions may hamper the appropriate data collection, enrollment into clinical trials, and appropriate p...
Copyright © 2012 Rie Nakamoto-Matsubara et al. This is an open access article distributed under the ...
AbstractBronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with l...
AbstractOther than lung transplantation (LT), no specific therapies exist for end-stage lung disease...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Introduction: Bronchiolitis Obliterans (BO) is one of the most important pulmonary complications of ...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Background The occurrence of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic ...
llogeneic and autologous haematopoietic stem cell (HSC) transplantation are now both established as ...
The term late-onset non-infectious pulmonary complications (LONIPCs) has been used to refer to event...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignan...
Copyright © 2012 Rie Nakamoto-Matsubara et al. This is an open access article distributed under the ...
AbstractBronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with l...
AbstractOther than lung transplantation (LT), no specific therapies exist for end-stage lung disease...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
Introduction: Bronchiolitis Obliterans (BO) is one of the most important pulmonary complications of ...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic ste...
Background The occurrence of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic ...
llogeneic and autologous haematopoietic stem cell (HSC) transplantation are now both established as ...
The term late-onset non-infectious pulmonary complications (LONIPCs) has been used to refer to event...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignan...
Copyright © 2012 Rie Nakamoto-Matsubara et al. This is an open access article distributed under the ...
AbstractBronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with l...
AbstractOther than lung transplantation (LT), no specific therapies exist for end-stage lung disease...